NCT04934618招募中2 期
A Single-arm, Multicenter, Open-labeled, Phase II Study on the Efficacy and Safety of Carelizumab Combined With Irinotecan and Apatinib in the Second-line Treatment of Locally Advanced Unresectable, Recurrent or Metastatic Adenocarcinoma of Stomach and Gastroesophageal Junction
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 85
- 试验地点
- 1
- 主要终点
- Overall Suvival time（OS）
研究概览
简要总结
The purpose of this study was to evaluate the overall survival time (OS), objective remission rate（ORR）, progression-free survival time（PFS）, disease control rate（DCR）of Carelizumab combined with irinotecan and apatinib for the second-line treatment of locally advanced unresectable, recurrent or metastatic adenocarcinoma of stomach and gastroesophageal junction. At the same time, the safety and tolerance of the scheme were preliminarily evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The local advanced stage confirmed by histopathology is unresectable, recurrent or metastatic Adenocarcinoma of stomach and gastroesophageal junction.
- •After receiving first-line treatment, the disease progressed or intolerable adverse reactions occurred.
- •At least one measurable lesion or evaluable lesion (according to RECIST 1.1 standard);
- •Patients agreed to provide blood samples and previously stored tumor tissue samples for tumor microenvironment detection.
- •Age ≥18 years old and ≤75 years old.
- •The ECOG score is 0 or
- •The estimated survival time is ≥3 months.
- •Within 7 days before entering the group, the laboratory test value met the chemotherapy standard.
- •Within 28 days before enrollment, women of childbearing age must confirm that the serum pregnancy test is negative and agree to adopt effective contraceptive measures during the study drug use and within 6 months after the last administration.
- •Patients voluntarily joined the study, signed informed consent, and were able to comply with the visit and related procedures stipulated in the plan.
排除标准
- •Participate in other intervention clinical studies at the same time (unless participating in observation studies or being in the follow-up stage of intervention studies), and have received second-line treatment.
- •have received antibody therapy of PD-1, PD-L1, PD-L2, CTLA4, CD137 or any other antibody or drug therapy with t cell co-stimulation or immune checkpoint pathway as specific target.
- •It is known to be allergic to any monoclonal antibody or adjuvant.
- •Received Chinese patent medicines with anti-tumor indications or drugs with immunoregulatory effects (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration.
- •Having undergone major surgery within 4 weeks before the first administration or expecting to undergo surgery during the study treatment.
- •Receive live attenuated vaccine within 4 weeks before the first administration or during the planned study treatment.
- •Received transplantation of solid organs or blood system.
- •Active, known or suspected autoimmune diseases or related medical history in the past 2 years (vitiligo, psoriasis, alopecia or Graves' disease that does not require systematic treatment in the past 2 years, hypothyroidism that only requires thyroid hormone replacement therapy, and type I diabetes patients who only need insulin replacement therapy can enter Group).
- •Immunosuppressive drugs have been used within 4 weeks before the first administration, excluding local glucocorticoid by nasal spray, inhalation or other routes or systemic glucocorticoid with physiological dose (i.e., prednisone or other glucocorticoid with equivalent dose not exceeding 10mg/ day), or hormone used due to allergy.
- •Known history of primary immunodeficiency disease.
- •Known history of active tuberculosis. 12 known to have a history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive).
- •after regular antihypertensive treatment, the blood pressure still cannot fall to the normal range (systolic blood pressure > >140mmHg, diastolic blood pressure > >90mmHg).
- •≥II grade ii coronary heart disease and arrhythmia (including QTc interval prolongation > >450ms for men and > >470ms for women).
- •Symptomatic congestive heart failure (new york Heart Association Grade II-IV) or symptomatic or poorly controlled arrhythmia.
- •before the first administration, there was toxicity caused by previous anti-tumor treatment that did not recover to grade 0 or grade 1 of the national cancer institute general adverse event terminology version 4.03 (NCI ctcae version 4.03) (excluding alopecia, fatigue and asymptomatic laboratory abnormalities).
- •abnormal coagulation function (INR > 1.5 uln, aptt > 1.5 uln), with bleeding tendency.
- •It is known that symptomatic central nervous system metastasis exists.
- •Diagnosed as other malignant tumors within 5 years before the first administration, excluding basal cell carcinoma of skin, squamous cell carcinoma of skin and carcinoma in situ after radical resection.
- •Active infections requiring treatment or systemic anti-infective drugs used within 7 days before the first administration.
- •acute or chronic active hepatitis b: HBV viral load ≥500 copies /ml
- •Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before the study.
- •It is known that there are mental diseases or drug abuse situations that may affect the compliance with the test requirements.
- •Acute or chronic active hepatitis C: HCV antibody is positive.
- •Pregnant or lactating women.
- •There are medical histories, diseases, treatments or abnormal laboratory results that may interfere with the test results and prevent the subjects from participating in the study, or the researchers think that participating in the study is not in the best interests of the subjects.
研究组 & 干预措施
Carelizumab Combined With Irinotecan and Apatinib
Experimental
Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）
干预措施: Carelizumab Combined With Irinotecan and Apatinib (Drug)
结局指标
主要结局
Overall Suvival time（OS）
时间窗: Up to 24 months
The time from randomization to death due to any reason. For those who have lost follow-up before death, the last follow-up time is usually calculated as the time of death.
次要结局
- Progress Free Survival time（PFS）(Up to 24 months)
- objective response rate（ORR）(Up to 24 months)
- duration of response （DoR）(Up to 24 months)
- Disease control rate（DCR）(Up to 24 months)
研究者
Shimin
Vice director of Oncology Department
Nanfang Hospital, Southern Medical University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced HepatocarcinomaAdvanced HepatocarcinomaNCT01418729Hospital Donostia216
进行中（未招募）
2 期
Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)Chronic Myeloid Leukemia, Chronic PhaseNCT04160546Fundacion CRIS de Investigación para Vencer el Cáncer80
Unknown
2 期
Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnifeLiver NeoplasmsNCT02363218Tianjin Medical University Cancer Institute and Hospital117
已完成
2 期
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory Philadelphia Positive B-precursor ALLNCT02000427Amgen45
已完成
不适用
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple MyelomaMultiple MyelomaNCT02474563Janssen Korea, Ltd., Korea171